Administration of Angiotensin-Converting Enzyme Inhibitors and <i>β</i>-Blockers During Adjuvant Trastuzumab Chemotherapy for Nonmetastatic Breast Cancer: Marker of Risk or Cardioprotection in the Real World?
Stefano Oliva(Istituto Tumori Bari), Silvia Sabatini(Istituto di Fisiologia Clinica), Luigi Tarantini(Santa Maria Nuova Hospital), Edda Simoncini(International Breast Cancer Study Group), Giovanni Pulignano(IRCCS San Camillo Hospital), Silvia Frattini(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Pompilio Faggiano(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Nicola Maurea(Cancer Institute (WIA)), Agnese Maria Fioretti(Istituto Tumori Bari), Francesco Giotta(Istituto Tumori Bari), Giovanni Cioffi(Casa di Cura Villa Bianca), Chiara Lestuzzi, L Boccardi
Cited by 49
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Burdens and Benefits of Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil and Tamoxifen for Elderly Patients With Breast Cancer: The International Breast Cancer Study Group Trial VII
|Journal of Clinical Oncology|2000|295
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
|The Lancet|2000|286
Prevalence and Prognostic Impact of Non-Cardiac Co-Morbidities in Heart Failure Outpatients with Preserved and Reduced Ejection Fraction: A Community-Based Study
|European Journal of Heart Failure|2018|174